Publications by authors named "Brendan Barry"
Article Synopsis
- The study aimed to evaluate dry eye disease (DED) using HLA-DR expression in conjunctival cells as an objective biomarker, rather than relying solely on subjective symptoms.
- Researchers analyzed data from DREAM study participants, including various ocular tests and 1,049 conjunctival samples to determine HLA-DR percentages and their correlation with DED signs and symptoms.
- Results showed significant variation in HLA-DR% across samples, with over 40% having low levels that may not effectively indicate DED, suggesting that this biomarker could help identify specific patient subgroups needing tailored treatment approaches.
Background: Diagnostic tests for dry eye disease (DED), including ocular surface disease index (OSDI), tear breakup time (TBUT), corneal fluorescein staining, and lissamine staining, have great deal of variability. We investigated whether fluorophotometry correlated with previously established DED diagnostic tests and whether it could serve as a novel objective metric to evaluate DED.
Methods: Dry eye patients who have had established signs or symptoms for at least 6 months were included in this observational study.
The omega-3 (ω3) and omega-6 (ω6) essential fatty acid knowledge base has been exploding. In the last 5 years, at least 12 clinical trials on ω3 and ω6 supplementation and dry eye disease (DED) were published in the peer-reviewed literature (2010 to 2015), about double the amount published in the 5 years prior. Although there is increasing scientific evidence that supports the potential use of ω3 and ω6 supplementation for DED, there are limited randomized controlled trials to properly inform evidence-based medicine.
View Article and Find Full Text PDF